

42. Levine MM. Typhoid fever vaccines. In: Plotkin S, Mortimer E, eds. Vaccines. 2d ed. Philadelphia: Saunders, 1994:597-633.
43. Yugoslav Typhoid Commission. Field and laboratory studies with typhoid vaccines. Bull World Health Organ 1957; 16:897-910.
44. Levine MM, Ferreccio C, Black RE, et al. Progress in vaccines against typhoid fever. Rev Infect Dis 1989; 11(suppl 3):S552-S567.
45. Ashcroft MT, Nicholason CC, Balwant S, et al. A seven-year field trial of two typhoid vaccines in Guiana. Lancet 1967; 2: 1056-1060.
46. Yugoslav Typhoid Commission. A controlled field trial of the effectiveness of acetone-dried and inactivated and heat-phenol-inactivated typhoid vaccines in Yugoslavia. Bull World Health Organ 1964; 30:623-630.
47. Pasteur L. Méthode pour prévenir la rage après morsure. CR Acad Sci Paris 1885; 101:765-772.
48. Pasteur L, Chamberland C, Roux E. Nouvelle communication sur la rage, avec la collaboraton de MM Chamberland et Roux. CR Acad Sci Paris 1884; 98:457-463.
49. Theiler M, Smith HH. The effect of prolonged cultivation in vitro upon the pathogenicity of yellow fever virus. J Exp Med 1937; 65:767-786.
50. Theiler M, Smith HH. The use of yellow fever virus modified by in vitro cultivation for human immunization. J Exp Med 1937; 65:787-800.
51. Klebs E. Ueber diphtherie. Verh Deut Kans Inn Med 1883; 2: 139-154.
52. Loeffler F. Untersuchungen uber die Bedeutung de Mikroorganismen fur die Entstehung der Diphtherie beim Menschen, bei der Taube und beim Kalbe. Mitt Klin Gesund Berlin 1884; 2:421.
53. Kitasato S. Ueber den Tetanusbacillus. Z Hyg 1889; 7:225-234.
54. Roux E, Yersin A. Contribution a l'étude de la diphthérie. Ann Inst Pasteur 1888; 2:629-661.
55. Park WH. Toxin-antitoxin immunization against diphtheria. JAMA 1922; 79:1584-1591.
56. Ramon G. L'anatoxine diphthérique. Ses propriétés—Ses applications. Ann Inst Pasteur 1928; 42:959-1009.
57. Glenney AT, Hopkins BE. Diphtheria toxoid as an immunizing agent. Br J Exp Pathol 1923; 4:283-288.
58. Besredka A. Local Immunization. Baltimore: Williams & Wilkins, 1927.
59. Sawtschenko J, Sabolotny DK. Versuch einer Immunisation des Menschen gegen Cholera. Zentralbl Allg Pathol Pathol Anat 1893; 4:625-636.
60. Russell AJH. Besredka's cholera bilivaccin versus anti-cholera vaccine: a comparative field test. In: Transactions of the Seventh Congress of the Far Eastern Association of Tropical Medicine, 1927, Calcutta, Vol 1. 1927:253.
61. Russell AJH. Le bilivaccin anticholérique et le vaccin anticholérique ordinaire. Essai de comparaison pratique. In: Graham JD, ed. Recherches Sur le Choléra et la Vaccination Anticholérique Dans l'Inde Britannique. Bull Off Int Hyg Publ 1928; 20: 703-709.
62. Russell AJH. Cholera in India. In: Transactions of the Ninth Congress of the Far Eastern Association of Tropical Medicine, 1934, Nanking, Vol. 1, 1934:398.
63. Sarramon. Sur l'emploi du vaccin anticholérique par vole buccale. Bull Soc Med Chir Indochine 1930; 8:180-183.
64. Davies A. An investigation into the serological properties of dysentery stools. Lancet 1922; 2:1009-1112.
65. Torikata R, Imaizuma M. Zum unterschiede zwischen der injektionen—und der oralen immunisierung. Z Immunitätsforsch 1938; 94:342-351.
66. Walsh TE, Cannon PR. Immunization of respiratory tract: a comparative study of the antibody content of the respiratory and other tissues following active, passive, and regional immunization. J Immunol 1938; 35:31.
67. Burrows W, Elliott ME, Havens I. Studies on immunity to cholera: IV. The excretion of coproantibody in experimental enteric cholera in the guinea pig. J Infect Dis 1947; 81:261-281.
68. Sabin AB. Behaviour of chimpanzee-avirulent poliomyelitis viruses in experimentally infected human volunteers. Am J Med Sci 1955; 230:1-8.
69. Salk JE, Bennett BL, Lewis LJ, et al. Studies in human subjects on active immunization against poliomyelitis: 1. A preliminary report of experiments in progress. JAMA 1953; 151:1081-1098.
70. Academy Forum. Experiments and Research with Humans: Values in Conflict. Washington, DC: National Academy of Sciences, 1975.
71. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. Research involving prisoners. Appendix to report and recommendations. DHEW publication No. (OS) 76-132, 1976.
72. Kerns T. Jenner on Trial: The Ethics of Vaccine Research in the Age of Smallpox and the Age of AIDS. Lanham, Maryland: University Press of America, 1997:1-116.
73. Casper WA. Spezifische cutieaktionen an gonorrhoeikern mit spezifischen, eiweiss-freien substanzen aus gonokokken. Klin Wochenschr 1930; 9:2154-2158.
74. Levine MM, Kaper JB, Herrington F, et al. Safety, immunogenicity and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103 HgR. Lancet 1988; 2:467-470.
75. Black RE, Levine MM, Clements ML, et al. Protective efficacy in humans of killed whole-*Vibrio* oral cholera vaccine with and without the B subunit of cholera toxin. Infect Immun 1987; 55:1116-1120.
76. Herrington D, Van de Verg L, Formal SB, et al. Studies in volunteers to evaluate candidate *Shigella* vaccines: further experience with a bivalent *Salmonella typhi-Shigella sonnei* vaccine and protection conferred by previous *Shigella sonnei* disease. Vaccine 1990; 8:353-357.
77. Herrington D, Clyde DF, Losonsky G, et al. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against *Plasmodium falciparum* sporozoites. Nature 1987; 328:257-259.
78. Clements ML, Betts RF, Murphy BF, et al. Advantage of live attenuated cold-adapted influenza virus over inactivated vaccine for A/Washington/80 (H3N2) wild-type infection. Lancet 1984; 1: 705-708.
79. Sunthurasamai P, Migasena S, Vongsthongsri U, et al. Clinical and bacteriological studies of El Tor cholera after ingestion of known inocula in Thai volunteers. Vaccine 1992; 10:502-505.
80. Minutes of the Meeting of the Vaccines and Related Biologic Products Advisory Committee to the Center for Biologics Evaluation and Research of the U.S. Food and Drug Administration. Use of Challenge Studies in Evaluation of Cholera Vaccines. January 26, 1993, Bethesda, MD.
81. Haffkine WM. Les vaccinations anticholériques aux Indes. Bull Inst Pasteur 1906; 4:697-737.
82. Haffkine WM. Protective inoculation against cholera. Calcutta 1913; 38-39.
83. Powell A. Further results of Haffkine's anticholera inoculation. J Trop Med Hyg 1899; 2:115.
84. MacLeod CM, Hodges RG, Heidelberger M, et al. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J Exp Med 1945; 82:445-465.
85. Francis T Jr., Korn RF, Voight RB, et al. An evaluation of the 1954 poliomyelitis vaccine trials. Summary report. Am J Public Health 1955; 45(5 part 2):1-50.
86. Wilson GS. The Hazards of Immunization. London: University of London, Athlone Press, 1967.
87. Berlin Correspondent. The Lübeck trial. Lancet 1932; 1:259-260.
88. Berlin Correspondent. The Lübeck trial. Lancet 1932; 1:365.
89. Anonymous. The Vienna antitoxin controversy. Lancet 1926; 2:1074-1075.
90. Jakovleva JL. Polyneurite diphthérique consecutive à l'injection de toxine diphthérique. Excerpted in: Bull Inst Pasteur 1927; 25:312.
91. Ten Broeck C, Chuan SH, Koch R. Diphtheria toxin-antitoxin mixture. China Med J 1927; 41:414-423.